Efficacy and Safety of Midostaurin-Based Induction and Maintenance Therapy for Newly Diagnosed AML


Efficacy and Safety of Midostaurin-Based Induction and Maintenance Therapy for Newly Diagnosed AML
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Stone RM et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Proc ASH 2015;Abstract 6.

Schlenk R et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose cytarabine (NCT01477606). Proc ASH 2015;Abstract 322.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.